MannKind Corp (MNKD): Long-Term Debt
$354.64M
As of 2025-12-31
$319.08M
As of 2026-06-30
+9.0%
3-year compound annual growth
+23.7%
5-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $354.64M | +883.7% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $36.05M | -86.6% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $268.70M | -1.8% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $273.49M | -2.7% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $281.20M | +130.1% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $122.23M | +2.8% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $118.90M | +16.0% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $102.49M | n/a | 2020-02-25, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| MannKind Corp (MNKD) | 2025-12-31 | $354.64M | +883.7% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $108.96M | +1.6% |
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $494.86M | +31.7% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $202.83M | +34.5% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $146.10M | +20.2% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $220.34M | -5.1% |
| Harrow, Inc. (HROW) | 2025-12-31 | $250.00M | -4.8% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $600.0K | -25.0% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $99.00M | +106.3% |
Compare MNKD, ARQT, SVA, ARDX side by side · Screen every company in Pharmaceutical Preparations ↗